With the start of the draft less than one week away, little movement is expected as it pertains to free agency. Dalton Risner ...

It’s the kind of call no one ever wants to make — but when they do, someone always answers. This week, during National Public ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the ...

Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon ...

Shares of DBV Technologies (DBVT) are moving lower after the company a “substantial doubt regarding its ability to continue as a going concern.” When reporting unaudited results for 2024 ...

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning.

DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants DBV sufficiently funded through the expected Biologics ...